AML Hub
The AML Hub is an open-access online resource dedicated to providing balanced, credible, and up-to-date medical education on acute myeloid leukemia (AML). Its aim is to enhance knowledge in AML through multichannel dissemination of global advances related to classification, diagnosis, treatment, and management.
Episodes
FLT3 inhibitors in AML: Current clinical landscape and key insights from trials
The AML Hub was pleased to speak with Mark J. Levis, Johns Hopkins University, Baltimore, US. We asked, What is the current clinical landscape of FLT3 inhibitors in the treatment of AML, and what insights have been gained from trials so far? Levis provides an overview of the key FLT3 inhibitors in clinical development for the treatment of FLT3-mutated (FLT3m) AML and discusses ongoing questions, i
Future directions for FLT3 inhibitors in AML treatment
The AML Hub was pleased to speak with Eytan Stein, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What might the future hold for the evolution of FLT3 inhibitors in the treatment of AML? Stein summarizes the approved indications for currently available FLT3 inhibitors and considers potential future directions for their investigation in the treatment of acute myeloid leukemia (AML)
Key questions in FLT3-mutated AML, and ongoing research to address these
The AML Hub was pleased to speak with Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK. We asked, What are the key ongoing questions in FLT3-mutated AML, and how are ongoing trials addressing these? Craddock begins by highlighting the progress made in the treatment of FLT3-mutated (FLT3m) acute myeloid leukemia (AML) over the past decade with two large randomized clinical tri
Menin inhibitors in AML: Where are we now, and where are we going?
During a meeting of the AML Hub Steering Committee, held on February 19, 2026, Jorge Cortes chaired a discussion on the topic, Menin inhibitors in AML: Where are we now, and where are we going? The discussion featured contributions from Charles Craddock, Brian Huntly, and Jeffrey Lancet. This educational resource is independently supported by Johnson & Johnson. All content was developed by SES
Managing side effects of menin inhibitors in clinical practice
The AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New York, US. We asked, What side effects are typically observed with menin inhibitor-based regimens, and how do you approach managing them in clinical practice? Roboz provides an overview of the key toxicities associated with menin inhibitor regimens in the treatment of NPM1-mutated (NPM1m) and KMT2A-rearranged (KMT2Ar) acu
Mechanisms and rationale for menin inhibitor combination strategies in AML
The AML Hub was pleased to speak with Eunice Wang from Roswell Park Comprehensive Cancer Center, Buffalo, US. We asked, What are the mechanisms and rationale for menin inhibitor combination strategies? Wang summarizes the rationale for menin inhibitor combination strategies for the treatment of NPM1-mutated (NPM1m) or KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML), including their potentia
Treatment decisions in AML: Personalizing care with FLT3 inhibitor therapy
During a meeting of the AML Hub Steering Committee, held on February 19, 2026, Jorge Sierra chaired a discussion on the topic, Treatment decisions in acute myeloid leukemia (AML): Personalizing care with FLT3 inhibitor therapy. The discussion featured contributions from Charles Craddock, Jorge Cortes, Hee-Je Kim, Jeffrey Lancet, Yasushi Miyazaki, Uwe Platzbecker, Roland Walter, and Agnieszka Wierz
What key insights are emerging from ongoing trials of menin inhibitor combination strategies in AML?
The AML Hub was pleased to speak with Joshua Zeidner, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, US. We asked, What key insights are emerging from ongoing trials of menin inhibitor combination strategies in AML? Zeidner provides an overview of currently approved menin inhibitors and discusses combination strategies in development for the treatment of NPM1-mut
Symposium | Understanding the differences between FLT3-ITD and -TKD mutations in AML: Q&A
The AML Hub held a virtual symposium on November 19, 2025, titled Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice. The symposium ended with a panel Q&A discussion with live audience participation. The panelists, Gail J. Roboz, Jorge Sierra, and Jorge Cortes, shared their per
Symposium | Implications for clinical practice: Managing AML with FLT3-ITD and -TKD mutations
The AML Hub held a virtual symposium on November 19, 2025, titled Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice. Here, we share a presentation from the symposium by Gail J. Roboz, Weill Cornell Medicine, New York, US, in which she discussed the management of patients with acute myeloid leukemia (AML) with FLT3-internal tandem duplicati
Symposium | Comparing treatment options for patients with FLT3-ITD and -TKD mutations
The AML Hub held a webinar on November 19, 2025, titled, Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice. Here, we share a presentation from the webinar by Jorge Cortes, Georgia Cancer Center, Augusta, US, discussing treatment options for patients with FLT3-ITD and -TKD mutations.Cortes describes the mechanisms of action of Type I and Ty
Symposium | FLT3 mutations in AML: Types, prevalence, and clinical significance
The AML Hub held a webinar on November 19, 2025, titled, “Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice.” Here, we share one of the presentations, by Jorge Sierra, Hospital de la Santa Creu i Sant Pau, Barcelona, ES, discussing the types, prevalence, and clinical significance of FLT3 mutations in acute myeloid leukemia (AML). Sierra pr
ASH 2025 | Pivekimab sunirine + Ven + Aza in unfit patients with ND CD123+ AML: Phase Ib/II efficacy and safety
Following the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New York, US. We asked, What are the latest findings from clinical trials of pivekimab sunirine in unfit patients with newly diagnosed acute myeloid leukemia (AML)?In this interview, Roboz discusses key fin
ASH 2025 | PARADIGM: Azacitidine + venetoclax vs conventional induction in fit adults with ND AML
Following the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the AML Hub was pleased to speak with Amir Fathi, Massachusetts General Hospital, Boston, US. We asked, How might the phase II PARADIGM trial data impact treatment decisions for newly diagnosed fit adults with acute myeloid leukemia (AML)?In this interview, Fathi discussed key fi
Clinical research round-up: Current and emerging treatments for IDH1-mutated AML
The AML Hub was pleased to speak with Eytan Stein, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What are the latest data presented on current and emerging treatments for acute myeloid leukemia (AML)? Stein starts by discussing therapies approved for the treatment of IDH1-mutated (IDH1m) AML, including ivosidenib and olutasidenib, and supporting data. He then considers strategies
Menin inhibitors in AML: Bridging the gap between trial data and clinical practice
The AML Hub was pleased to speak with Emma Searle, The Christie NHS Foundation Trust, Manchester, UK. We asked for her thoughts on the topic “Menin inhibitors in AML: Bridging the gap between trial data and clinical practice.” Searle summarizes the key considerations when using menin inhibitors in the treatment of NPM1-mutated (NPM1m) or KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML) in cl
Addressing uncertainty in patient selection for transplant in AML
During a meeting of the AML Hub Steering Committee, held on July 22, 2025, Charles Craddock chaired a discussion on the topic: Addressing uncertainty in patient selection for transplant. The discussion featured contributions from Jessica Altman, Courtney DiNardo, Jeffrey Lancet, Roland Walter, and Joshua Zeidner. Hosted on Acast. See acast.com/privacy for more information.
Integrating menin inhibitors into the treatment landscape of AML: Future directions
The AML Hub was pleased to speak with Joshua Zeidner, Associate Professor of Medicine at the University of North Carolina Lineberger Comprehensive Cancer Center in Durham, North Carolina. We asked for his thoughts on the topic “Integrating menin inhibitors into the treatment landscape of AML: Future directions”. Zeidner provides an overview of the latest clinical trial data on menin inhibitors in
Know AML webinar | Closing remarks and Q&A
Know AML conducted a healthcare professional (HCP) and patient webinar on April 23, 2025, titled ‘Mutation testing in AML: What you need to know’. Here, we share closing remarks and questions from the audience addressed by the chair, Charles Craddock, Queen Elizabeth Hospital Birmingham, UK; Gail J. Roboz, Weill Cornell Medicine, New York, US; and Ralph Hills, Connecticut, US.T
Know AML webinar | How can physicians and patients communicate more clearly about mutation testing in AML going forward?
This independent educational activity is supported by Thermo Fisher Scientific. All content is developed independently by the faculty. The funder is allowed no influence on the content. Know AML hosted a webinar for patients and healthcare professionals (HCPs) on April 23, 2025, titled ‘Mutation testing in AML: What you need to know’. Here, we share a discussion between Gail J. Robo
Know AML webinar | Empowering patients to ask their physician the right questions during their AML journey
Know AML hosted a webinar for patients and healthcare professionals (HCPs) on April 23, 2025, titled ‘Mutation testing in AML: What you need to know’. Here, we share a discussion between Gail J. Roboz, physician at Weill Cornell Medicine and Know AML Ambassador, and Ralph Hills, Know AML Chair, where they considered the range of genetic mutations in AML and what they mean for treatments, and also
Know AML webinar | What are mutations, and why do they matter in AML?
Know AML hosted a webinar for patients and healthcare professionals (HCPs) on April 23, 2025, titled ‘Mutation testing in AML: What you need to know’. Here, we share a presentation by the chair, Charles Craddock, Queen Elizabeth Hospital Birmingham, UK, discussing mutations and why they matter in AML. This independent educational activity is supported by Thermo Fisher Scientific. All content
“How I treat” a patient with DNMT3A-mutated AML in remission post intensive chemotherapy
The AML Hub was pleased to speak with Cristina Papayannidis, Universitaria di Bologna, Bologna, IT. We asked, How do you treat a patient with DNMT3A-mutated acute myeloid leukemia (AML) in remission post intensive chemotherapy?This educational resource is independently supported by Bristol Myers Squibb. All content is developed by SES in collaboration with an expert steering committee; funders are
CPX-351 as first-line treatment in AML: Real-world data
Here, we summarize five real-world studies presented at EHA 2024 on real-world outcomes of patients with AML who received CPX-351 as a first-line treatment. Hosted on Acast. See acast.com/privacy for more information.
What is the impact of the 5th WHO classification and ICC of AML on diagnosis and treatment of high-risk AML?
The AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New York, US. We asked, What is the impact of the 5th World Health Organization (WHO) classification and International Consensus Classification (ICC) of AML on diagnosis and treatment of high-risk acute myeloid leukemia (HR AML)? In this interview, Roboz walks through the changes in the classification criteria for AML
What were your highlights from ASH 2023?
During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, Michal Bar-Natan, Weill Cornell Medicine, New York, US, shared her highlights with the AML Hub. Hosted on Acast. See acast.com/privacy for more information.
What are the challenges associated with CAR T-cell therapy in patients with AML?
During the 6th European CAR T-Cell Meeting, the AML Hub spoke to Sarah Tettamanti, Tettamanti Foundation Research Center, Monza, IT. We asked, What are the challenges associated with CAR T-cell therapy in patients with AML? Hosted on Acast. See acast.com/privacy for more information.
How might the MORPHO trial of gilteritinib impact clinical practice?
The AML Hub spoke to Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK at ASH 2023. We asked, How might the MORPHO trial of gilteritinib impact clinical practice? Hosted on Acast. See acast.com/privacy for more information.
Risk stratification and guidelines in AML management
The AML Hub was pleased to speak to Gail Roboz, Weill Cornell Medicine, New York, US, and Naval Daver, MD Anderson Cancer Center, Houston, US. We asked about risk stratification and guidelines in acute myeloid leukemia (AML) management. Firstly, Roboz and Daver discuss the impact of blast count on the diagnosis of AML and how a patient's mutational profile can affect treatment decisions
How are new fludarabine conditioning combinations impacting transplant outcomes?
During the virtual 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke with Eleni Gavriilaki, George Papanikolaou General Hospital of Thessaloniki, Thessaloniki, GR. We asked, How are new fludarabine conditioning combinations impacting transplant outcomes?Gavriilaki begins by discussing a study presented at EBMT 2022 that explored outcomes of
Should pre-transplant MRD be used to guide treatment in AML?
During the EHA2021 Virtual Congress, the AML Hub spoke with Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, Should pre-transplant measurable residual disease (MRD) be used to guide treatment in AML?Nagler begins by discussing the importance of MRD in AML treatment and transplantation. He highlights the significance of MRD in different settings as a prognosis factor and describes the res
Should pre-transplant MRD be used to guide treatment in AML?
During the EHA2021 Virtual Congress, the AML Hub spoke with Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK. We asked, Should pre-transplant minimal residual disease (MRD) be used to guide treatment in acute myeloid leukemia (AML)?Craddock begins by outlining the reasons for the increased use of allogeneic transplant and reviews data that discuss the exclusion criteria a
Should pre-transplant MRD be used to guide treatment in AML?
During the EHA2021 Virtual Congress, the AML Hub spoke with Gert Ossenkoppele, Amsterdam UMC, Amsterdam, NL. We asked, Should pre-transplant minimal residual disease (MRD) be used to guide treatment in acute myeloid leukemia (AML)? Ossenkoppele begins by outlining emerging techniques in MRD, such as next-generation sequencing. He goes on to describe how risk category and MRD status can inform
Can HMA maintenance therapy improve eligibility for HSCT?
During the 2021 TCT Meetings Digital Experience, the AML Hub spoke to Farhad Ravandi, MD Anderson Cancer Center, Houston, US. We asked, Can HMA maintenance therapy improve eligibility for HSCT? Ravandi begins by highlighting the limited maintenance approaches for patients with AML. He continues with the promising results from the QUAZAR AML-001 study evaluating oral azacitidine (CC-486), an o
ALLG AMLM16: Does sorafenib plus intensive chemotherapy improve outcome in FLT3-ITD AML?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Andrew Wei, The Alfred Hospital, Melbourne, AU, and Natasha S. Anstee, The Alfred Hospital & Monash University, Melbourne, AU. We asked, Does sorafenib plus intensive chemotherapy improve outcome in FLT3-internal tandem duplication (FLT3-ITD) AML?Wei starts by introducing the clinical
Venetoclax combinations in mutant AML subtypes: IDH1/2
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Daniel Pollyea, University of Colorado School of Medicine, Aurora, US, about venetoclax combinations in patients with AML with IDH1/2 mutations.Clinical studies evaluating the combination of venetoclax + azacitidine versus azacitidine alone have shown that patients with AML with IDH1/2 mutation
Venetoclax combinations in mutant AML subtypes podcast: FLT3
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Naval Daver, MD Anderson Cancer Center, Houston, US, about venetoclax combinations in patients with FLT3-mutated AML.Emerging data on venetoclax combinations in patients with FLT3-mutated AML have been presented at ASH 2020. FLT3 mutations are the most common mutations in patients with AML
Introduction to a series of podcasts on the use of venetoclax combinations in mutation subtypes of AML
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Courtney D. DiNardo, MD Anderson Cancer Center, Houston, US, about the use of venetoclax combinations in mutation subtypes of AML.In this podcast, DiNardo gives an overview of the studies on venetoclax combinations presented at ASH 2020, especially venetoclax plus azacitidine, in mutation subty
How close are we to offering treatment tailored to mutational profile?
During the European School of Haematology (ESH) 2nd How to Diagnose and Treat: Acute Leukaemia meeting, the AML Hub spoke to Jorge Sierra, Hospital de la Santa Creu i Sant Pau, Barcelona, ES. In this podcast, Jorge Sierra talks about how close we are to offering treatment tailored to mutational profile. Jorge Sierra describes the clinical benefit of adding drugs that target mutations into tre
Approaches and emerging therapies for TP53 AML
During the 25th Congress of the European Hematology Association (EHA), the AML Hub spoke to a member of our steering committee, Naval Daver, The University of Texas MD Anderson Cancer Center, Houston, US, about novel approaches and emerging therapies for TP53 AML.Identification of disease-driving genetic aberrations has allowed for major advancements in the AML setting. TP53 mutations are observed
How can we use the microbiome to improve cancer immunotherapy and alleviate side effect such as graft-versus-host-disease
During the American Association of Cancer Research (AACR) Virtual Annual Meeting I, the AML Hub was pleased to speak to Christine Spencer, Parker Institute for Cancer Immunotherapy, San-Francisco, US and Diwakar Davar, University of Pennsylvania Medical Center, Pittsburgh, US. We asked: how can we use the microbiome to improve cancer immunotherapy and alleviate side effects such as graft-versus-ho
Can CD47 antibody therapy be safely used for AML and MDS?
During the 25th Congress of the European Hematology Association (EHA), the AML Hub hosted a discussion between David Sallman, Moffitt Cancer Center, Tampa, US, and Steering Committee Member Naval Daver, MD Anderson Cancer Center, Houston, US.The question was, Is CD47-directed antibody therapy safe and effective in patients with AML and myelodysplastic syndromes?CD47 is a dominant negative immune c
How does the type of prior treatment affect the risk of therapy-related myeloid neoplasms?
During the American Society of Clinical Oncology (ASCO) Annual Meeting, Alexander Maurer from the AML Hub hosted a group discussion with Michael Ozga and Caner Saygin, both from The Ohio State University, Columbus, US and Abhay Singh from Roswell Park Comprehensive Cancer Center, Buffalo, US. This podcast discusses how the type of prior treatment can affect the risk of therapy-related myeloid neop
Recommended
English Made Simple
Trauma Bonding to Secure Relationship
Lucy & Sam's Perfect Brains
The ADHD Adults Podcast
Swingers
Messy Social Work
Africa's not for Wimps
The Psychology Perspective
Write Me Dirty with Katherine Ryan
RHISE: Real History in Simple English (A2-B1, British)
Quickly Kevin; will he score? The 90s Football Show
The Jon Richardson Show on Absolute Radio
